Patent Foramen Ovale

Publication Date: April 29, 2020

Key Points

Key Points

  • For patients with cryptogenic stroke and PFO, percutaneous PFO closure probably reduces the risk of stroke recurrence (HR-0.41, summary rate difference -0.67% per year), probably is associated with a periprocedural complication rate of 3.9%, and probably is associated with the development of serious non-periprocedural atrial fibrillation (RR-2.72, summary rate difference 0.33% per year).
  • For patients with cryptogenic stroke and PFO, anticoagulation medication and antiplatelet medication are possibly equally effective at reducing recurrent stroke.

Management

...nagement...

...ommendations Regarding Percutaneou...

...ng considered for PFO closure, clinicians should...

...ing considered for PFO closure, clin...

...s being considered for PFO closure, clinicians sh...

...atients being considered for PFO closure, c...

...t patients being considered for PFO...

...eing considered for PFO closure, clin...

...patients being considered for PFO clos...

...being considered for PFO closure, clinicians may...

...ore undergoing PFO closure, patients should...

...higher risk alternative mechanism of...

...dergoing PFO closure, patients shoul...

...ents with a PFO detected after stroke...

...ger than 60 years with a PFO and an embolic-app...

...inform patients that presence of a large...

PFO closure may be offered in othe...

...re may be offered to younger patients (e.g.,...

...whom PFO closure is being considered, a sha...


Recommendations Regarding Medical Thera...

...n patients who opt to receive medical the...

...would otherwise be considered good candid...


...igure 1. Management Algorit...